There have been aspirations for closer collaboration between European Union (EU) Member States (MS) on Health Technology Assessment (HTA) for at least two decades.
European Commission (EC) has approved Pfizer’s Trazimera, for breast and gastric cancer treatment, marking it as pharma’s first oncology biosimilar to receive approval in the EU.
The European Commission (EC) is proposing to adjust intellectual property (IP) rules to help Europe's pharma companies tap into fast-growing global markets.